Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NK510 in advanced NSCLC
NCT06097962Phase 1Recruiting
- Sponsor
- Base Therapeutics
- Start
- Jul 2023
- Primary completion
- Jul 2027
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label trial of NK510 in non-small cell lung cancer (NSCLC) (5 arms), sponsored by Base Therapeutics. Primary endpoints: Dose-limiting toxicity and incidence of adverse events at 6 weeks and Objective Response Rate at 6 weeks. Started Jul 2023; status: recruiting.
02
Drugs
NK510
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06097962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06097962.